Health and Healthcare
Why Neos Therapeutics Shares Are Hitting a New Low
Published:
Last Updated:
Neos Therapeutics Inc. (NASDAQ: NEOS) saw its shares sink to a new 52-week low after the company announced that it had priced its secondary offering of common stock. Neos priced its 5.0 million shares at $5 each, with an overallotment option for an additional 750,000 shares. At this price, the entire offering is valued up to $28.75 million. The offering is expected to close on February 8.
Cowen and BMO Capital Markets are acting as joint-book running managers, and JMP Securities is acting as a lead manager for the offering.
This pharmaceutical company is focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platform, which it already has used to develop its approved product Adzenys XR-ODT and two product candidates for the treatment of attention deficit hyperactivity disorder (ADHD).
The approved product and two product candidates are extended-release (XR) medications in patient-friendly, orally disintegrating tablets (ODT), or oral suspension dosage forms.
Neos received approval from the U.S. Food and Drug Administration (FDA), for Adzenys XR-ODT, its amphetamine XR-ODT, on January 27, 2016, and began the commercialization of this product on May 16, 2016.
In July 2016, the firm announced that it had completed the bridging study demonstrating that the Cotempla XR-ODT to-be-marketed product was bioequivalent to the clinical trial material, and in December 2016, Neos announced the resubmission of its NDA for Cotempla XR-ODT. Additionally, in November 2016, it announced the submission of an NDA for NT-0201, an amphetamine XR oral suspension.
The company intends to use the proceeds from this offering to further develop its pipeline and fund its studies, as well as paying down its debt. The remainder will be used for working capital and general corporate purposes.
Shares of Neos were last seen down 14% at $4.97 on Friday, with a consensus analyst price target of $21.00 and a 52-week trading range of $4.90 to $11.75.
Sponsored: Want to Retire Early? Here’s a Great First Step
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
